Literature DB >> 12074779

Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination.

Patrik Finne1, Anssi Auvinen, Jussi Aro, Harri Juusela, Liisa Määttänen, Sakari Rannikko, Matti Hakama, Teuvo L J Tammela, Ulf-Håkan Stenman.   

Abstract

BACKGROUND AND
OBJECTIVE: Approximately 70% of the men with an elevated serum prostate-specific antigen (PSA) identified in prostate cancer screening do not have prostate cancer. Other available diagnostic variables may be utilized to reduce the number of false positive PSA results, but few algorithms for calculation of the combined impact of multiple variables are available. The objective of this study was to establish nomograms showing the probability of detecting prostate cancer at biopsy on the basis of total PSA, and the percentage of free PSA in serum, prostate volume and digital rectal examination (DRE) findings.
METHODS: In a randomized, population-based prostate cancer screening trial 10284 men aged 55-67 years were screened during 1996 and 1997 in two metropolitan areas in Finland. Results for men (n=758) with a serum PSA of 4-20 microg/l were used to establish the risk nomograms. Of these 200 (26%) had prostate cancer at biopsy.
RESULTS: Prostate cancer probability depended most strongly on the percentage of free PSA. Total PSA, prostate volume, and DRE also contributed to prostate cancer probability, whereas age and family history of prostate cancer did not. More false positive PSA results could be eliminated by using the multivariate risk model rather than the percentage of free PSA (p<0.001) or PSA density (p=0.003) alone.
CONCLUSIONS: Wide variation in probability of detecting prostate cancer among screened men with a serum PSA of 4-20 microg/l was observed. The nomograms established can be used to avoid or defer biopsy in men with a low prostate cancer probability in spite of a serum PSA level exceeding 4 microg/l.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12074779     DOI: 10.1016/s0302-2838(02)00179-3

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  11 in total

1.  Prospective evaluation of operating characteristics of prostate cancer detection biomarkers.

Authors:  Yuanyuan Liang; Donna P Ankerst; Norma S Ketchum; Barbara Ercole; Girish Shah; John D Shaughnessy; Robin J Leach; Ian M Thompson
Journal:  J Urol       Date:  2010-11-12       Impact factor: 7.450

2.  Variations in prostate biopsy practice: A quantitative questionnaire-based study.

Authors:  Matthew O Lipinski; D Robert Siemens; Patti A Groome
Journal:  Can Urol Assoc J       Date:  2013 Nov-Dec       Impact factor: 1.862

3.  Cancer Progress and Priorities: Prostate Cancer.

Authors:  Kevin H Kensler; Timothy R Rebbeck
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-02       Impact factor: 4.254

4.  Diagnostic performance of 68Ga-PSMA PET/CT in the detection of prostate cancer prior to initial biopsy: comparison with cancer-predicting nomograms.

Authors:  Jingliang Zhang; Shuai Shao; Peng Wu; Daliang Liu; Bo Yang; Donghui Han; Yu Li; Xiaoyu Lin; Wei Song; Milin Cao; Jing Zhang; Fei Kang; Weijun Qin; Jing Wang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-11       Impact factor: 9.236

5.  Nonlinear modeling was applied thoughtfully for risk prediction: the Prostate Biopsy Collaborative Group.

Authors:  Daan Nieboer; Yvonne Vergouwe; Monique J Roobol; Donna P Ankerst; Michael W Kattan; Andrew J Vickers; Ewout W Steyerberg
Journal:  J Clin Epidemiol       Date:  2014-11-29       Impact factor: 6.437

6.  Actual Contribution of Free to Total PSA Ratio in Prostate Diseases Differentiation.

Authors:  Alden Prcic; Edin Begic; Mustafa Hiros
Journal:  Med Arch       Date:  2016-07-27

7.  The establishment and evaluation of a new model for the prediction of prostate cancer.

Authors:  Qi Wang; Yan-Feng Li; Jun Jiang; Yong Zhang; Xu-Dong Liu; Ke Li
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

8.  Tumour Markers: Rationale Use.

Authors:  Mathias M Müller; Marietta Vogl
Journal:  EJIFCC       Date:  2005-05-17

9.  Correlation of transrectal ultrasonographic findings with histo pathology in prostatic cancer.

Authors:  Farooq Ahmad Ganie; Mohd Saleem Wanie; Shabir Ahmad Ganie; Hafezulla Lone; Masaratul Gani; Mohd Farooq Mir; Naseer Ahmad Khan
Journal:  J Educ Health Promot       Date:  2014-05-05

Review 10.  Key Enabling Technologies for Point-of-Care Diagnostics.

Authors:  Elisabetta Primiceri; Maria Serena Chiriacò; Francesca M Notarangelo; Antonio Crocamo; Diego Ardissino; Marco Cereda; Alessandro P Bramanti; Marco A Bianchessi; Gianluigi Giannelli; Giuseppe Maruccio
Journal:  Sensors (Basel)       Date:  2018-10-24       Impact factor: 3.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.